You want to rapidly bring your cancer treatment to patients as quickly and safely as possible. We can help. From preclinical and clinical support to regulatory strategy, we provide access to tools, resources and scientific expertise to fast-track your program through every research milestone.Get Started
Launch your development the right way with a start-to-finish preclinical strategy. As a TD2 client, you’ll have access to best-in-class immuno-oncology models, from multiplex cytokines to more than 300 human tumor xenograft models and more. We have exactly what you need, when you need it.Get Started
Understand how your oncology drug performs in biological systems with testing related to solubility, permeability, protein binding, metabolism, oral/IV bioavailability, pharmacokinetic activity and more. We pair all efficacy studies with full DMPK resources in our leading-edge facility co-located with our AAALAC-accredited vivarium.Get Started
Speed up your drug’s pathway to cancer patients with a regulatory package that fully complies with FDA and ICH guidelines. We’re there with you at every regulatory junction, from interactions with agencies during pre-IND and INTERACT meetings to IND submissions, CMC development and nonclinical testing services.Get Started
Get faster results with our complete array of clinical services, customized just for you. All packages include support for clinical trial management, study strategy, enrollment, medical writing and an adaptive database so that you can access the FDA’s tools and opportunities for expedited drug development.Get Started
Translational Drug Development (TD2) is a world-class drug development organization specializing in getting the newest and best oncology treatments to cancer patients as quickly as possible.
Fast-track your research with an integrated and diverse suite of preclinical tools, from more than 300 personalized models to provide strong experimental support for your strategy to bioanalytical and ADME support services.
Find trial-ready patients, even for rare diseases, with a real-time searchable database of millions of cancer patients in community oncology practices.
From pre-IND evaluations through filing and maintenance support, we’ll help you along the path to approval and beyond—including strategy, meetings, paperwork and everything in between.
“Development of new medicines requires both the best possible preclinical and clinical science. It also demands working with a great sense of urgency. The TD2 team provides innovative solutions that give new medicines the best chance to work for patients with cancer. With expert capabilities that support early discovery, pharmacokinetics, regulatory affairs and clinical development through Phase II, TD2 represents a comprehensive solution for oncology-focused companies.”
Daniel D. Von Hoff, MD, FACP, Chief Development Officer - TD2
“TD2 has a rich scientific heritage and has successfully identified, translated and applied -omics driven outcomes to speed the development of new oncology medicines, and to identify those cancer patients most likely to have clinical benefit from these new drugs.”
Jeffrey Trent, PhD, FACMG, President and Research Director - Translational Genomics Research Institute (TGen)
If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. Contact us to get started today!